A propósito de la onconefrología: enfermedad renal crónica en pacientes oncológicos no hospitalizados

Benito, Manuel Heras; García, Lucila; Luis, María José Fernández-Reyes

doi:10.1016/j.nefro.2019.04.004

Cited by 2 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proteinuria is a known CKD and cardiovascular mortality-related factor ( 1 , 7 , 9 , 18 ). In the subgroup analysis, we found that among initial non-progressors, there was a significant relationship between higher ACR and transformation to progressor at 12 and 24 months.…”

Section: Discussionmentioning

confidence: 99%

“…Different studies establish a relationship between kidney disease and comorbidities such as hypertension, DM, or HF ( 4 , 5 , 7 , 9 ). In the present study, it was challenging to find a solid correlation between the different comorbidities studied and risk of progression.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is essential to design screening strategies to select patients who may benefit from closer monitoring in order to avoid a healthcare system overload ( 5 , 6 , 9 , 12 , 13 ). According to the Spanish consensus document for the detection and management of CKD ( 14 ), patients >80 years with no evidence of progression and no significant albuminuria could remain under GP follow-up even with an eGFR <30 mL/min/1.73m2.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors

Frías

Vargas²,

Pérez³

et al. 2023

Front. Nephrol.

View full text Add to dashboard Cite

BackgroundThe current definition of chronic kidney disease applied to patients over the age of 80 has increased the number of referrals to Nephrology. However not all of these patients may benefit from its assessment. This study aims to analyze the evolution of ≥80 years old patients referred to Nephrology.MethodsSingle-center study including patients ≥80 years old with eGFR <60 mL/min/1,73m2 who were referred to Nephrology consultation for the first time. Clinical and analytical parameters were collected retrospectively 12 months before the visit, and prospectively at baseline, and 12 and 24 months after the initial visit. We divided patients into two groups based on annual eGFR loss: progressors (>5 mL/min/1.73m2) and non-progressors (≤5 mL/min/1,73m2).ResultsA total of 318 patients were included, mean age was 84,9 ± 4 (80-97) years. Baseline serum creatinine was 1,65 ± 0,62 mg/dL, eGRF 35 (28-42) mL/min/1,73, and albumin/creatinine ratio 36 (7-229) mg/g. 55,7% of the patients met the definition of progressor at baseline (initial-progressors), 26,3% were progressors after a 12-month follow-up and 13,4% after 24 months. 21,2% and 11,4% of initial-progressors met this definition at 12 and 24 month follow up. The main risk factor for progression was albuminuria. No relationship was found between the nephrologist intervention and the evolution of renal function among initial non-progressors.ConclusionElderly patients who have stable renal function at the time of referral will continue to have stable renal function over the subsequent 24 months and thus may not need to be referred to a nephrologist.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors

Frías

Vargas²,

Pérez³

et al. 2023

Front. Nephrol.

View full text Add to dashboard Cite

show abstract

“…The analysis of thromboelastometry results also allowed for the assessment of clot lysis. This is important from the perspective of the reports [ 36 – 38 ] on the increased risk of hyperfibrinolysis in patients with ESRD. We did not observe such cases in our study.…”

Section: Discussionmentioning

confidence: 99%

Assessment of haemostasis and impact of fibrinogen supplementation on clot properties using global haemostasis assays in patients on chronic dialysis

Pluta¹,

Nicińska²,

Durlik³

et al. 2020

ait

View full text Add to dashboard Cite

Patients with end-stage renal disease (ESRD) are at increased risk of haemostasis disorders which result from changes in plasma and platelet (PLT) components [1]. Haemodialysis (HD) is the most common method of treatment used in patients with ESRD [2]. The contact between blood and the artificial surfaces of dialysis machines increases PLT reactivity and the production of coagulation factors. Consequently, this may lead to the occurrence of coagulopathy. It may also affect the natural process of blood clot dissolution (fibrinolysis) [3]. Concomitantly, damage in the vascular endothelium and changes in the activity of proteins participating in the coagulation cascade during the course of the ESRD may pose a risk of haemorrhage [1]. Furthermore, HD may only replace about 10% of proper

show abstract

A propósito de la onconefrología: enfermedad renal crónica en pacientes oncológicos no hospitalizados

Cited by 2 publications

References 5 publications

Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors

Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors

Assessment of haemostasis and impact of fibrinogen supplementation on clot properties using global haemostasis assays in patients on chronic dialysis

Contact Info

Product

Resources

About